1. Home
  2. BANR vs MLYS Comparison

BANR vs MLYS Comparison

Compare BANR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banner Corporation

BANR

Banner Corporation

HOLD

Current Price

$61.84

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.93

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANR
MLYS
Founded
1890
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.9B
IPO Year
2015
2023

Fundamental Metrics

Financial Performance
Metric
BANR
MLYS
Price
$61.84
$26.93
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$71.20
$48.67
AVG Volume (30 Days)
280.1K
1.2M
Earning Date
04-22-2026
03-12-2026
Dividend Yield
3.30%
N/A
EPS Growth
15.57
37.43
EPS
5.64
N/A
Revenue
N/A
N/A
Revenue This Year
$0.73
N/A
Revenue Next Year
$5.69
N/A
P/E Ratio
$10.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.01
$10.44
52 Week High
$69.83
$47.65

Technical Indicators

Market Signals
Indicator
BANR
MLYS
Relative Strength Index (RSI) 59.64 53.43
Support Level $61.73 $26.85
Resistance Level $65.31 $31.09
Average True Range (ATR) 1.25 1.59
MACD 0.42 0.41
Stochastic Oscillator 99.33 68.09

Price Performance

Historical Comparison
BANR
MLYS

About BANR Banner Corporation

Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: